NICE's Unrestricted MS Indication For Lemtrada Could Boost It Ahead Of Rivals

Though not totally convinced about long-term effectiveness and patient adherence, NICE's decision not to restrict Lemtrada's indication could place it ahead of Gilenya and Tysabri for relapsing-remitting multiple sclerosis.